Group 1 - The company reported a strong performance in the first half of 2025, with total revenue of 3.4 billion yuan, a year-on-year increase of 20%, and a net profit attributable to shareholders of 640 million yuan, up 30% year-on-year [1] - In Q2 2025, the company achieved a revenue of 1.85 billion yuan, a 25% increase year-on-year, and a net profit of 370 million yuan, reflecting a 28% year-on-year growth, aligning with preliminary reports [1] - Key growth drivers include increased investment in the oil and gas sector in the Middle East, high demand for oil service equipment, and strong orders from major clients like Saudi Aramco and ADNOC [1] Group 2 - The company maintained a high gross margin of 35.8% in the first half of 2025, an increase of 0.3 percentage points year-on-year, while the net profit margin rose to 18.9%, up 1.5 percentage points year-on-year [2] - The company implemented a stock incentive plan in July 2025, granting 7.714 million restricted shares to 154 key personnel, aimed at enhancing team motivation and aligning interests [2] - The company forecasts net profits of 1.5 billion, 1.8 billion, and 2.1 billion yuan for 2025-2027, with corresponding P/E ratios of 17, 14, and 12 times [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 2025年6月17日，公司召开第十一届董事会2025年度第十次会议及第十一届监事会2025年度第五次会 议，审议通过了《关于回购注销部分限制性股票的议案》。具体内容详见公司2025年6月18日于上海证 券交易所网站（www.sse.com.cn）披露的《厦门国贸集团股份有限公司关于回购注销部分限制性股票的 公告》（公告编号：2025-46）。 证券代码：600755 证券简称：厦门国贸 编号：2025-50 厦门国贸集团股份有限公司 股权激励限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●回购注销原因：厦门国贸集团股份有限公司（以下简称"公司"）2022年限制性股票激励计划（以下简 称"2022年激励计划"）中70名激励对象因架构调整、工作调动等原因调动至厦门国贸控股集团有限公司 或其下属企业任职，50名激励对象因离职，4名激励对象因退休，不再具备激励资格；公司2022年激励 计划首次授予第三个解除限售期和预留授予第二个解除限售期公 ...

Group 1 - The company will hold its first extraordinary general meeting of shareholders in 2025 on September 9, 2025, and voting will be conducted through the Shenzhen Stock Exchange trading system and internet voting system [1][2][3] - The company has not been subject to any regulatory measures or penalties from securities regulatory authorities or exchanges in the past five years [8][9] - The company plans to issue A-shares to specific targets in 2025, with a total fundraising amount estimated at 4 billion yuan, assuming the maximum issuance of 100 million shares [10][13] Group 2 - The company has outlined measures to mitigate the dilution of immediate returns resulting from the issuance, including enhancing fundraising management and accelerating project construction [21][22] - The company emphasizes the importance of maintaining a stable profit distribution policy and protecting investor rights, with a three-year shareholder return plan in place [24][26] - The company has committed to ensuring that the measures for compensating diluted returns will be effectively implemented by its board and senior management [26][28] Group 3 - The company has adjusted the exercise price of stock options in its incentive plan due to annual profit distribution, with the new exercise price set at 52.55 yuan per share [49][56] - The implementation of the company's stock incentive plan has positively impacted team stability, with the turnover rate of incentive targets significantly lower than the industry average [57]

Core Viewpoint - The company has completed the cancellation of 46 stock options from its 2023 stock option and restricted stock incentive plan, which were not exercised by the designated incentive recipient within the first exercise period [2][15]. Group 1: Stock Option and Incentive Plan Overview - The company held a board meeting on July 10, 2023, to approve the draft of the 2023 stock option and restricted stock incentive plan, along with related management methods [4]. - The company completed the first grant registration of stock options, totaling 5,757,384 options, on September 14, 2023 [6]. - The first grant registration of restricted stock, totaling 420,000 shares, was completed on October 10, 2023 [7]. Group 2: Cancellation of Stock Options - The cancellation of the stock options was due to the expiration of the first exercise period, which ended on July 25, 2025, for the options that were not exercised [14]. - The company has completed the cancellation procedures with the Shenzhen branch of China Securities Depository and Clearing Co., Ltd. [15]. - The cancellation of these stock options is in compliance with relevant regulations and will not adversely affect the company's financial status or the ongoing implementation of the incentive plan [16].

Core Viewpoint - The document outlines the legal opinions regarding the acquisition of assets by Anhui Guofeng New Materials Co., Ltd. through the issuance of shares and cash payment, along with the associated fundraising and related party transactions [1][2]. Group 1: Legal Framework and Compliance - The law firm Anhui Tianhe has been appointed to provide legal advice on the transaction, ensuring compliance with relevant laws and regulations such as the Company Law and Securities Law [1][2]. - The firm has issued previous legal opinions and supplementary opinions regarding the transaction, indicating a thorough review process [2][3]. Group 2: Employee Stock Ownership Plan - The document discusses the employee stock ownership platform, Taohu Jinzhang Enterprise Management Consulting Partnership, which has undergone multiple changes in partnership shares, raising questions about the valuation and transfer pricing [3][4]. - The historical performance and valuation of the target assets are scrutinized, particularly regarding the differences in share repurchase prices compared to previous capital increases [4][12]. Group 3: Valuation and Pricing - The valuation for the capital increase in January 2022 was set at 12.031 yuan per share, with a pre-investment valuation of approximately 1 billion yuan [12][13]. - The repurchase price for shares in January 2024 was determined based on the company's financial performance and market conditions, with a total valuation of 600 million yuan [14][15]. Group 4: Transaction Developments - The company has maintained good communication with the transaction counterpart, Su Quan, who decided to withdraw from the transaction due to personal information disclosure concerns, leading to the signing of a termination agreement [16]. - The stock incentive plan is progressing, with the company planning to use repurchased shares for employee incentives, ensuring that the plan remains intact despite the ongoing transactions [17][18]. Group 5: Financial Reporting and Accounting - The document outlines the accounting treatment for share-based payments, confirming that the recognition of share payment expenses is accurate and reasonable according to accounting standards [20][21]. - The total share payment expenses to be recognized over the service period are detailed, indicating a structured approach to financial reporting [21].

上海市锦天城（深圳）律师事务所 关于广州赛意信息科技股份有限公司 部分已授予但尚未归属的 2020 年、2021 年、2022 年限制性 股票相关事项的 法律意见书 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21-23 层 电话：0755-82816698 传真：0755-82816898 邮编：518000 上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于广州赛意信息科技股份有限公司 已授予但尚未归属的 2020 年、2021 年、2022 年限制性股票相关 事项的法律意见书 致：广州赛意信息科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、《深圳证券交易所创业板股票上市规则》《深 圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》以及《广州赛 意信息科技股份有限公司章程》等有关规定，上海市锦天城（深圳）律师事务所 （以下简称"本所"）接受广州赛意信息科技股份有限公司（以下简称"赛意信 息"或"公司"）的委托，就赛意 ...

Core Points - The company held its 13th meeting of the third Supervisory Board on August 21, 2025, via telecommunication, which complied with relevant laws and regulations [1] - The Supervisory Board approved the full semi-annual report for 2025, confirming its compliance with legal standards and accuracy [1][2] - The company plans to invest an additional $10.5 million in its joint venture in Singapore, PharmaGend Global Medical Services Pte. Ltd., to support infrastructure and operational needs [3][4] - The adjustments to the stock incentive plans for 2021, 2022, and 2023 were approved, ensuring compliance with relevant regulations and not harming shareholder interests [5][6] - The board confirmed that the conditions for the fourth vesting period of the 2021 stock incentive plan were met, but the stocks will remain unsold until January 26, 2026 [6] - The conditions for the third vesting period of the 2022 stock incentive plan were also met, with stocks remaining unsold until January 27, 2026 [7] - The board agreed to void unvested stocks from the 2021, 2022, and 2023 incentive plans due to the departure of certain employees and unmet performance targets [8][9]

上海妙道企业管理咨询有限公司 关于 康龙化成（北京）新药技术股份有限公司 第四个归属期归属条件成就相关事项 之 独立财务顾问报告 独立财务顾问： 二〇二五年八月 上海妙道企业管理咨询有限公司 独立财务顾问报告 一、董事会就本次激励计划设定的限制性股票归属条件是否成就的审议情况 .....10 二、本次归属条件成就之日和第四个归属期限制性股票继续禁售的说明 .........13 上海妙道企业管理咨询有限公司 独立财务顾问报告 第一章 声 明 上海妙道企业管理咨询有限公司接受委托，担任康龙化成（北京）新药技 术股份有限公司（以下简称"康龙化成""上市公司"或"公司"）2021 年 A 股限制性股票激励计划（以下简称"本激励计划"）的独立财务顾问（以下简 称"本独立财务顾问"），并制作本独立财务顾问报告。本独立财务顾问报告 是根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股权 激励管理办法》《深圳证券交易所创业板上市公司自律监管指南第 1 号——业 务办理》等法律、法规和规范性文件的有关规定，在康龙化成提供有关资料的 基础上，发表独立财务顾问意见，以供康龙化成全体股东及有关各方参考。 一、本独立财 ...

Core Viewpoint - The independent financial advisor report by Shanghai Miaodao Enterprise Management Consulting Co., Ltd. confirms that the conditions for the third vesting period of the 2022 A-share restricted stock incentive plan of Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. have been met, although the stocks will not be listed immediately [1][10]. Group 1: Approval Process - The board of directors and the supervisory board approved the incentive plan and its related matters in multiple meetings held in March and May 2022 [6][7]. - The company conducted a public announcement of the list of incentive objects, which received no objections during the public notice period [6][7]. - The board and supervisory board held meetings in July 2022 to approve adjustments to the grant price and quantity of the restricted stocks [7]. Group 2: Vesting Conditions - The third vesting period for the restricted stocks is defined as the first trading day after 36 months from the grant date until the last trading day within 48 months from the grant date, allowing for a vesting ratio of 25% of the total granted stocks [11]. - The company’s 2024 revenue must increase by at least 60% compared to the 2021 revenue, which was approximately 7.44 billion yuan, to meet the performance conditions [13]. - A total of 336 incentive objects met the personal performance evaluation criteria, with 100% of them qualifying for the vesting [15]. Group 3: Stock Listing and Trading Restrictions - The vesting date for the restricted stocks is set for July 28, 2025, but the stocks will remain under a trading restriction for six months post-vesting [18]. - The company will apply for the listing of the vested stocks after the trading restriction period ends on January 27, 2026 [18]. Group 4: Independent Financial Advisor's Opinion - The independent financial advisor confirms that all conditions for the vesting of the restricted stocks have been satisfied and that the necessary approvals have been obtained, ensuring compliance with relevant laws and regulations [19].

北京市中伦律师事务所 关于康龙化成（北京）新药技术股份有限公司 个归属期归属条件成就但股票暂不上市 及部分限制性股票作废事项的 法律意见书 二〇二五年八月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭 州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 法律意见书 目 录 北京市中伦律师事务所 关于康龙化成（北京）新药技术股份有限公司 第四个归属期归属条件成就但股票暂不上市 及部分限制性股票作废事项的 法律意见书 致：康龙化成（北京）新药技术股份有限公司 根据康龙化成（北京）新药技术股份有限公司（以下简称"康龙化成"、 "公 司"）与北京市中伦律师 ...